[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Psychiatric Research Unit, Region Zealand, Denmark\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":76},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100566471","external-trigeminal-nerve-stimulation-for-attention-deficit-hyperactivity-disorder---feasibility-trial-100566471",false,"NCT06655610","External Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder - Feasibility Trial","External Trigeminal Nerve Stimulation Versus Sham Stimulation for Attention Deficit Hyperactivity Disorder in Children and Adolescents Aged 7-17 Years: Study Protocol for a Pilot and Feasibility Randomized Clinical Trial","eTNS4ADHD","Inclusion Criteria:\n\n* 7 to 17 years of age at the time of study enrollment.\n* A clinical diagnosis of ADHD according to criteria for ICD-10: F90.0, F91.0, F90.8, F90.9, F98.8C. The ADHD diagnosis must be verified by the Diagnostic and Statistical Manual for Mental Disorders (DSM-5) using The Schedule for Affective Disorders and Schizophrenia for School-aged Children (K-SADS).\n* A score above 24 on the ADHD rating scale (ADHD-RS) at baseline.\n* Signed informed consent from parents\u002Flegal caretakers and from the patients aged ≥ 15.\n\nWe will include treatment-naïve patients, patients who previously have received stimulant medication, and patients in stable, ongoing stimulant medication (methylphenidate or dexamphetamines\u002Flisdexamphetamine) during the time of the trial.\n\nExclusion Criteria:\n\n* Patients receiving atomoxetine and guanfacine at the time of study enrollment will be excluded all together\n* Epilepsy\n* Electronic or metallic implants.\n* Serious mental and\u002For somatic diseases other than ADHD, such as:\n\n  * Pervasive developmental disorder not including Asperger's syndrome (ICD-10 F84.0-84.4 + F84.8-84.9)\n  * Schizophrenia\u002Fparanoid psychosis (ICD-10 F20-25 + F28-29)\n  * Mania or bipolar disorder (ICD-10 F30 and F31)\n  * Depressive psychotic disorders (ICD-10 F32.3 + F33.3)\n  * Substance dependence syndrome (ICD-10 F1x.2)\n  * Cardio-vascular disorders\n  * Cancer\n* An Intelligence quotient (IQ) below 70 measured by the Wechsler Intelligence Scale for Children\n* A substantial degree of restless sleep as reported by parents or caregivers and evaluated by the physician.\n* Other disabilities that may make use of Monarch problematic.","ALL","7 Years","17 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","The investigators will assess the use of the Monarch eTNS device as a non-pharmacological treatment for patients aged 7 to 17 years with ADHD.\n\nThe investigators will compare the eTNS device to a sham device. Participants will use the device for four weeks during night time. During the trial, participants will receive different questionaires to assess symptoms and will also keep a logbook to record their experience with the device.\n\nAt the end of trial, the investigators will assess what the families thought of the device, and whether it is indeed feasible to further explore the effect of the device in a larger clinical trial.",[28],"ADHD - Attention Deficit Disorder With Hyperactivity",[30,31,32,33],"ADHD","Neuromodulation","External trigeminal nerve stimulation","feasibility trial","RECRUITING","2026-03-05",{"date":37,"type":38},"2026-03-09","ACTUAL",{"date":40,"type":38},"2024-12-05",{"date":42,"type":22},"2026-11-25",{"name":44,"class":45},"Psychiatric Research Unit, Region Zealand, Denmark","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":46},"100482453","the-effect-of-creatine-monohydrate-on-persistent-post-concussive-symptoms-100482453","NCT05562232","The Effect of Creatine Monohydrate on Persistent Post-concussive Symptoms","The Effect of Creatine Monohydrate on Persistent Post-concussive Symptoms - a Pilot Study Protocol","Inclusion Criteria:\n\n* Have had PPCS for a minimum of six months and a maximum of 18 months at the start of the study.\n* Being between 20 and 45 years of age\n\nExclusion Criteria:\n\n* Elite athletes, as well as people who in general is physical active, at an intensity of moderat to high, for more than ten hours a week on average.\n* Participation in other interventions\u002Ftreatment that could affect this study\n* Have had PPCS in:\n* =\\\u003C6 months\n* =\\>18 months\n* Pregnant","20 Years","45 Years",{"count":57,"type":22},45,[25],"The purpose of this study, is to investigate whether creatine monohydrate as a supplement reduces the number and severity of symptoms in patients with persistent post-concussive symptoms through self-reported post-concussion symptoms questionnaires.",[61,62],"Mild Traumatic Brain Injury","Concussion, Brain",[64,65,66,67],"Concussion","Mild traumatic brain injury","Creatine monohydrate","Persistent post-concussive symptoms","2024-07-11",{"date":70,"type":38},"2024-07-12",{"date":72,"type":38},"2023-08-01",{"date":74,"type":22},"2024-12-31",{"name":44,"class":45},""]